Logo
Richesse Collafilo

Richesse Collafilo

Richesse

Skin Booster
  • Manufactured by JDBIO Co., Ltd., a Korean company producing medical and aesthetic collagen products under quality Controlled conditions.
  • Marketed in some regions with CPNP Related variants and professional Use labelling; specific CE or MHRA device registrations are not publicly detailed and should be verified locally before clinical use.
  • Intended strictly for professional use in accordance with local regulations governing injectable collagen fillers and biostimulators.
  • Clinics are advised to ensure that product sourcing, storage, handling and administration comply with national regulatory and professional standards.
Atelo collagen biostimulatory collagen filler for facial rejuvenation and contouring

Description

Richesse Collafilo is a high-purity, absorbable atelo collagen (3%) biostimulatory skin booster and collagen filler designed to restore youthful vitality, elasticity and firmness to the skin. Formulated with 3% atelo collagen in combination with hyaluronic acid and poly L-lactic acid (PLA), it stimulates the skin’s own collagen, elastin and hyaluronic acid production, improving texture, tone and volume over time. Its telopeptide-free atelo collagen significantly reduces antigenicity and immune reactions, providing excellent biocompatibility and biodegradability. Richesse Collafilo is indicated for facial rejuvenation and contouring, effectively reducing fine lines, wrinkles and deep folds (such as nasolabial folds), enhancing consistent volume in treated areas and supporting tissue regeneration. It can be used on the face, neck, décolletage and hands by trained professionals for natural-looking, long-lasting results.

Bnefits

  • Contains 3% high-purity atelo collagen to stimulate the skin’s natural collagen production and improve elasticity and firmness.
  • Acts as a dual-purpose regenerative filler, providing volume and contour while supporting long-term tissue regeneration.
  • Effectively reduces the appearance of wrinkles, fine lines and deeper folds such as nasolabial folds and marionette lines.
  • Enhances consistent, natural-looking volume in treated areas with high viscoelasticity that helps maintain facial shape without deformation.
  • Boosts the production of endogenous hyaluronic acid and elastin, improving hydration, skin density and overall skin quality.
  • Promotes cell growth, tissue regeneration and hemostasis, making it suitable for both facial rejuvenation and selected wound-healing indications in clinical settings.
  • Atelo collagen with removed telopeptides minimises immune reactions, offering low allergenicity and excellent biocompatibility.
  • Biodegradable and bioabsorbable, gradually resorbed by the body while leaving behind newly formed collagen for long-lasting improvement.
  • High viscosity and stable gel structure help to firm loosened tissue and restore brightness and pigmentation to ageing or photo-damaged skin.
  • Packaged as a sterile 1 ml prefilled syringe with fine-gauge needles, providing controlled injection and predictable distribution for professional use.

Indications

  • Facial rejuvenation for loss of firmness, elasticity and volume.
  • Reduction of fine lines and wrinkles, including perioral and periorbital lines when appropriate technique is used.
  • Treatment of deeper folds such as nasolabial folds and marionette lines.
  • Cheek augmentation and contouring to restore mid-face volume.
  • Improvement of skin texture, tone and radiance in areas affected by collagen loss.
  • Rejuvenation of neck and décolletage skin showing signs of ageing and laxity.
  • Hand rejuvenation to improve skin quality and reduce crepey appearance.
  • Adjunctive use in tissue regeneration and wound-healing protocols where atelo collagen supplementation is indicated and permitted by local regulations.

Composition

  • Atelo collagen 3% (high-purity, telopeptide-removed collagen; atelocollagen) as the primary biostimulatory component.
  • Poly L-lactic acid (PLA) as a collagen-stimulating polymer to support long-term neocollagenesis and structural improvement.
  • Hyaluronic acid (HA) to provide initial hydration, viscoelasticity and lubrication for smoother injection and distribution.
  • Sterile buffered aqueous solution (exact buffer components not publicly specified) to maintain physiological pH and osmolality.
  • No added lidocaine in the base formulation (analgesia to be provided separately according to clinical protocol where required).

Formulation

  • Subdermal collagen regeneration filler composed of 3% atelo collagen in a sterile injectable gel.
  • High-viscosity, high-viscoelasticity formulation designed to loosen and then firm skin tissue, providing stable shaping and lifting.
  • Biodegradable, bioabsorbable atelocollagen matrix with reduced antigenicity through removal of terminal telopeptides.
  • Incorporates PLA and HA to enhance collagen stimulation and injection smoothness while supporting hydration.
  • Supplied as a 1.0 ml prefilled glass syringe intended for single use, with 30G needles for precise subdermal delivery.
  • Non-animal, medical-grade collagen source marketed as highly consistent with human skin collagen and safe for soft-tissue implantation when used appropriately.

Packaging

  • Box containing 1 x 1.0 ml prefilled syringe of Richesse Collafilo.
  • Includes 2 x 30G sterile disposable needles for injection (commonly 30G x 13 mm).
  • Sterile blister pack for syringe and needles to maintain asepsis until use.
  • Outer carton printed with product name (Richesse Collafilo), main composition (Atelo Collagen 3%), volume (1.0 ml), lot number, expiry date, origin (Korea) and manufacturer branding (RICHESSE / JDBIO).
  • Intended for professional clinic use; each syringe is single-use and must not be resterilised or reused.

Usage

  • For professional use only: Richesse Collafilo must be administered exclusively by qualified medical or aesthetic practitioners who are trained in injection techniques and facial anatomy.
  • Before treatment, obtain a complete medical history, including allergies (particularly to collagen, PLA, HA or any injectable biomaterials), autoimmune conditions, coagulation disorders, current medications (especially anticoagulants or antiplatelets) and previous aesthetic procedures.
  • Examine the treatment area (face, neck, décolletage, hands) and assess degree of volume loss, wrinkles and skin quality; discuss realistic expectations, potential risks and alternative options with the patient and obtain informed consent.
  • Cleanse the treatment area thoroughly and disinfect with an appropriate antiseptic solution. Maintain strict aseptic technique throughout the procedure.
  • Inspect the syringe and packaging; do not use if the blister is damaged, the syringe has been opened, the product is past its expiry date, or the contents show discoloration, particulates or phase separation.
  • Attach one of the supplied 30G needles securely to the luer-lock tip of the syringe; expel any air bubbles and prime the needle by gently depressing the plunger until a small droplet appears.
  • Inject into the deep dermis or subcutaneous tissue depending on the indication and anatomical site (e.g., subdermal for nasolabial folds and marionette lines, supraperiosteal or deep subcutaneous for cheek augmentation, mid-dermal/subdermal for general rejuvenation).
  • Use appropriate injection techniques such as serial puncture, linear threading, fanning, or small bolus injections to achieve even distribution and desired contour; inject slowly with controlled pressure.
  • Where clinically appropriate, aspirate before injecting to help reduce the risk of inadvertent intravascular injection; never inject into or directly adjacent to blood vessels.
  • Avoid overcorrection during the initial session; aim for conservative volume since additional collagen will form over time and touch-up sessions can be scheduled later if needed.
  • After injection, gently mould the treated area with fingertips to distribute the product evenly and smooth contours, avoiding aggressive massage that may cause displacement or bruising.
  • Provide post-treatment advice: patients should avoid makeup on treated areas for at least 12 hours, refrain from intense heat or cold exposure (sauna, steam rooms, tanning beds, ice packs directly on skin), vigorous exercise and alcohol for 24–48 hours, and protect treated areas from UV exposure with broad-spectrum sunscreen.
  • Advise patients to avoid massaging or pressing on treated areas unless specifically instructed and to sleep with the head slightly elevated on the first night to help minimise swelling.
  • Explain that collagen stimulation is gradual: visible improvements in firmness and texture develop over weeks to months; follow-up sessions may be recommended depending on the treatment plan.
  • Dispose of used needles, syringe and any remaining product as clinical sharps and pharmaceutical waste; Richesse Collafilo is single-use and must not be reused or resterilised.

Contraindications

  • Known hypersensitivity or allergy to collagen, atelocollagen, PLA, hyaluronic acid or any other component of the product.
  • History of severe allergic reactions or anaphylaxis to injectable biomaterials.
  • Active skin infections, inflammatory skin diseases, or unhealed wounds in the intended treatment area.
  • Autoimmune diseases or immunosuppressive conditions, unless the treating physician determines that treatment is appropriate after careful risk–benefit assessment.
  • Bleeding disorders or patients receiving high-dose anticoagulant or antiplatelet therapy, unless managed in collaboration with the patient’s physician.
  • Pregnancy and breastfeeding (not recommended due to lack of sufficient safety data).
  • Patients under 18 years of age.
  • Tendency to form hypertrophic scars or keloids in the area to be treated.
  • Previous permanent fillers or foreign body implants in the same site, unless thoroughly evaluated and deemed safe by an experienced practitioner.
  • Intravascular injection, injection into highly vascularised danger zones without appropriate precautions, or use in areas where compromised vascularity is present is strictly contraindicated.

Adverse Effects

  • Typical transient injection-site reactions such as redness (erythema), swelling (oedema), pain or tenderness, warmth and mild bruising.
  • Small lumps or nodules at injection points that usually resolve spontaneously or with gentle massage; persistent nodules may require medical evaluation.
  • Temporary asymmetry, contour irregularities or over/undercorrection, which may need adjustment or follow-up treatment.
  • Rare inflammatory or hypersensitivity reactions including prolonged redness, swelling, induration or itching at the treated area.
  • Infection at injection sites, potentially leading to cellulitis or abscess formation if aseptic technique or aftercare is inadequate (rare).
  • Rare risk of granuloma formation or delayed-onset nodules requiring specific management by an experienced clinician.
  • Vascular complications if injected into or compressing a vessel, potentially leading to blanching, severe pain, livedo, tissue ischaemia or necrosis; extremely rare but serious events such as visual disturbances or blindness can occur if embolisation affects ocular circulation.
  • Systemic vasovagal responses (e.g., lightheadedness, nausea, transient syncope) in susceptible individuals during or after injections.

Storage Conditions

  • Store between 2°C and 8°C in a refrigerator; do not freeze.
  • Keep in the original blister and outer carton to protect from light and contamination until the time of use.
  • Do not use the product after the expiry date printed on the packaging.
  • Do not use if the syringe or packaging is damaged, opened or shows signs of improper storage.
  • Allow the product to reach room temperature before injection as per practitioner preference, without exceeding the recommended storage conditions.
  • Keep out of the sight and reach of children and unauthorised persons.

Duration

Clinical and distributor data indicate that the biostimulatory and volumising effects typically last around 12 to 18 months, with continued collagen support for many months; duration depends on treatment area, dose, technique and individual patient factors such as metabolism and lifestyle.

Onset

Some immediate improvement in volume and skin smoothness is visible after injection due to the filler matrix, while more pronounced improvements in elasticity, firmness and wrinkle reduction develop gradually over several weeks to months as new collagen is synthesised.

Browse more Skin Booster

Top Treatments

Top Cities in the UK